Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

Cited In for PubMed (Select 19786678)

1.

Patient-reported and actionable safety events in CKD.

Ginsberg JS, Zhan M, Diamantidis CJ, Woods C, Chen J, Fink JC.

J Am Soc Nephrol. 2014 Jul;25(7):1564-73. doi: 10.1681/ASN.2013090921. Epub 2014 Feb 20.

PMID:
24556352
2.

A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate.

Goraya N, Simoni J, Jo CH, Wesson DE.

Clin J Am Soc Nephrol. 2013 Mar;8(3):371-81. doi: 10.2215/CJN.02430312. Epub 2013 Feb 7.

3.

Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.

Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K.

Clin J Am Soc Nephrol. 2012 Aug;7(8):1234-41. doi: 10.2215/CJN.01150112. Epub 2012 May 17.

4.

Hypertension in Cardiovascular and Kidney Disease.

Botdorf J, Chaudhary K, Whaley-Connell A.

Cardiorenal Med. 2011;1(3):183-192. Epub 2011 Jul 30.

5.

Estimated net endogenous acid production and serum bicarbonate in African Americans with chronic kidney disease.

Scialla JJ, Appel LJ, Astor BC, Miller ER 3rd, Beddhu S, Woodward M, Parekh RS, Anderson CA.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1526-32. doi: 10.2215/CJN.00150111. Epub 2011 Jun 23.

6.

Aging and antihypertensive medication-related complications in the chronic kidney disease patient.

Marcum ZA, Fried LF.

Curr Opin Nephrol Hypertens. 2011 Sep;20(5):449-56. doi: 10.1097/MNH.0b013e32834902ad. Review.

7.

Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs.

Uijtendaal EV, Zwart-van Rijkom JE, van Solinge WW, Egberts TC.

Eur J Clin Pharmacol. 2011 Sep;67(9):933-40. doi: 10.1007/s00228-011-1028-1. Epub 2011 Mar 19.

8.

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, Shahinfar S, Grobbee D, de Zeeuw D.

Diabetologia. 2011 Jan;54(1):44-50. doi: 10.1007/s00125-010-1922-6. Epub 2010 Sep 30. Erratum in: Diabetologia. 2011 Aug;54(8):2209.

9.

Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril.

Johnson ES, Weinstein JR, Thorp ML, Platt RW, Petrik AF, Yang X, Anderson S, Smith DH.

Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):266-72. doi: 10.1002/pds.1923.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk